Paediatric Acute Leukaemia Translocations (Accredited)


The WHO classification of haematopoietic tumours uses genetic markers to aid in the classification of Precursor Lymphoid Neoplasms. The identification of the t(12;21) (TEL-AML1 or ETV6-RUNX1), t(4;11) (KMT2A-AFF1 or MLL-AF4) and t(1;19) (E2A-PBX1 or TCF3-PBX1) are useful diagnostic tools and also have prognostic significance that allow for therapeutic stratification.


In this programme participants are provided with lyophilised cell-lines for t(12;21) (TEL-AML1 or ETV6-RUNX1), t(4;11) (KMT2A-AFF1 or MLL-AF4) and t(1;19) (E2A-PBX1 or TCF3-PBX1) analysis. Participants are asked to submit qualitative results, together with details of the methodology. All samples mimic diagnostic specimens and are therefore not suitable for MRD analysis; this may be subject to change dependent on participants’ feedback. Instructions for storage, reconstitution and use of the lyophilised samples are included with the samples. Three send-outs are issued per annum, with each send-out consisting of two samples.


Pre issue testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.


To register for this programme, please click here.

Example Paediatric Acute Leukaemia Translocations Report
Example PALT Report.pdf
Adobe Acrobat document [741.1 KB]
Paediatric Acute Leukaemia Translocations Performance Monitoring System
PALT Performance Monitoring System.pdf
Adobe Acrobat document [194.8 KB]
Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube


Last updated 14th December 2018 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information, please click here.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).